The Drug Pricing Summit Pharma Wasn't Invited To
Does the Trump-Cummings confab mean that drug makers are doomed to price negotiations in Medicare Part D? (Answer: Almost certainly not, but this is Trump we're talking about.)
You may also be interested in...
House Oversight Committee Ranking Member Jim Jordan suggests that Congress may need to re-evaluate the length of pharma patents and FDA exclusivities.
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.